Defence Therapeutics has enhanced its internal capabilities in purification, analytical characterization, conjugation development, and quality control to advance its ACCUM-enabled Antibody Drug Conjugates (ADC) pipeline. The company acquired new equipment and improved workflows to ensure consistent, high-quality ADC candidates, supporting its partnership programs. These upgrades aim to speed up candidate selection and validation, positioning Defence as a leader in ADC development and manufacturing. The company expects these improvements to accelerate the creation of more effective cancer therapies with reduced side effects.
Bitcoin dropped 2.5% to about $62,674 on June 23, pressured by the Federal Reserve's hawkish outlook and six consecutive weeks of Bitcoin ETF outflows totaling over $6 billion in the past month. The Fed's stance on maintaining or raising interest rat...
Engineering and construction costs continued to increase in June, according to the Engineering and Construction Cost Indicator by PEG and S&P Global Market Intelligence. However, fewer respondents reported higher prices, with the materials and equipm...
Arbitrum's ARB token is under significant bearish pressure, dropping roughly 96% from its all-time high and experiencing double-digit losses in the last 24 hours. Long traders faced liquidations totaling over $750,000, while shorts lost under $7,500,...
NETSOL Technologies has formed a strategic partnership with Stockholm-based Applicon Financial Solutions to accelerate its expansion in the Nordic region. This collaboration aims to help Nordic banks and finance companies modernize their core technol...
At PetroTal's annual general meeting on June 23, 2026, shareholders representing 43.3% of shares approved all resolutions, including electing eight directors, appointing Deloitte LLP as auditors, granting share units, and authorizing a share consolid...
